Confronting the Complexity of Targeting the PI3K/AKT/mTOR Pathway in Cancer

Speakers: Bryan Hennessy, Fabrice André, Cristian Massacesi, and Anastasios Stathis

Panellists discuss different aspects important for rational clinical development of PI3K/Akt/mTOR inhibitors: what can we learn from studying biomarkers and resistance mechanisms? How can we build on this knowledge?

Discussion Points

  • How to build on from what we know now in the preclinical and clinical settings?
  • mTOR inhibition in breast cancer: clinical aspects and toxicity
  • In which cancers is the pathway involved?
  • Where are we in studying biomarkers?
  • PI3K inhibition in haematological malignancies: a short description
  • How are PI3K inhibitors close to the clinic?